- ISIN
- US36269B1052
- CUSIP
- 36269B105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 18, 2021
Highlights
- Market Cap
- $75.59M
- Enterprise Value
- $59.47M
- EPS (TTM)
- -$0.60
- Gross Profit (TTM)
- $2.13M
- EBITDA (TTM)
- -$19.59M
- Year Range
- $1.41 - $4.34
- Target Price
- $9.00
- ROA (TTM)
- -113.35%
- ROE (TTM)
- -151.64%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GANX Performance Chart
Gain Therapeutics, Inc. (GANX) is down 44.4% since the beginning of the year. At $2 per share, GANX is trading 58.8% below its 52-week high of $4. Investors who bought $1,000 worth of GANX shares 5 years ago would now be looking at an investment worth $168.
Loading charts...
Returns By Period
Gain Therapeutics, Inc. (GANX) has returned -44.41% so far this year and -10.95% over the past 12 months.
Gain Therapeutics, Inc.
- 1D
- -2.19%
- 1M
- -5.79%
- YTD
- -44.41%
- 6M
- -46.08%
- 1Y
- -10.95%
- 3Y*
- -28.66%
- 5Y*
- -29.99%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
GANX Monthly Returns History
Based on dividend-adjusted daily data since Mar 18, 2021, GANX's average daily return is +0.01%, while the average monthly return is -0.37%.
Historically, 41% of months were positive and 59% were negative. The best month was Nov 2025 with a return of +78.6%, while the worst month was Jun 2024 at -49.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, GANX closed higher 45% of trading days. The best single day was Feb 24, 2026 with a return of +31.1%, while the worst single day was Dec 18, 2025 at -44.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -44.10% | 45.00% | -25.67% | -2.58% | 3.17% | -8.21% | -44.41% | ||||||
| 2025 | -1.39% | 0.00% | -10.33% | 7.33% | -13.66% | 1.69% | -18.89% | 36.30% | -11.06% | 10.73% | 78.57% | -8.00% | 49.07% |
| 2024 | 18.53% | 16.02% | -16.04% | -22.28% | -12.97% | -49.80% | -15.62% | 0.93% | 63.30% | 40.45% | -25.60% | 16.13% | -33.84% |
| 2023 | 26.20% | 5.32% | 15.87% | 4.36% | -8.35% | -2.82% | -11.38% | -16.62% | -0.91% | -12.80% | -25.17% | 52.57% | 4.31% |
| 2022 | -26.34% | -7.75% | 10.84% | -16.38% | -12.87% | 20.81% | 10.56% | -13.32% | -5.51% | 2.45% | -8.98% | 2.96% | -42.36% |
| 2021 | 33.21% | -19.04% | -12.33% | -5.57% | -20.00% | -2.50% | -4.55% | -6.51% | 4.02% | -25.00% | -51.52% |
Benchmark Metrics
Gain Therapeutics, Inc. has an annualized alpha of -13.09%, beta of 1.12, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since March 19, 2021.
- This stock participated in 86.69% of S&P 500 Index downside but only -49.35% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -13.09%
- Beta
- 1.12
- R²
- 0.05
- Upside Capture
- -49.35%
- Downside Capture
- 86.69%
Return for Risk
Risk / Return Rank
GANX ranks 41 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Gain Therapeutics, Inc. (GANX) and compare them to S&P 500 Index.
| GANX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.10 | 2.24 | -2.34 |
Sortino ratioReturn per unit of downside risk | 0.69 | 3.07 | -2.38 |
Omega ratioGain probability vs. loss probability | 1.09 | 1.41 | -0.31 |
Calmar ratioReturn relative to maximum drawdown | -0.18 | 2.93 | -3.11 |
Martin ratioReturn relative to average drawdown | -0.31 | 13.52 | -13.83 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Gain Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Gain Therapeutics, Inc. was 94.08%, occurring on Aug 13, 2024. The portfolio has not yet recovered.
The current Gain Therapeutics, Inc. drawdown is 88.67%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -94.08%Aug 2024 | 3y 4mo | — | 5y 2moApr 2021 - now |
2021 pullback2021 | -7.95%Mar 2021 | 0s | 3d | 3dMar 2021 - Mar 2021 |
Drawdown Indicators
| GANX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.08% | -56.78% | -37.30% |
Max Drawdown (1Y)Largest decline over 1 year | -61.96% | -9.10% | -52.86% |
Max Drawdown (3Y)Largest decline over 3 years | -81.50% | -18.90% | -62.60% |
Max Drawdown (5Y)Largest decline over 5 years | -91.21% | -25.43% | -65.78% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -88.67% | -0.74% | -87.93% |
Average DrawdownAverage peak-to-trough decline | -75.45% | -10.72% | -64.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.32% | 1.97% | +33.35% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Gain Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Gain Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GANX in comparison with other companies in the Biotechnology industry. Currently, GANX has a P/B value of 5.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GANX
Add Gain Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GANX